Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers

BACKGROUND: After several exploratory and confirmatory clinical trials, the intralesional administration of human recombinant epidermal growth factor (hrEGF) has been approved for the treatment of advanced diabetic foot ulcers (DFU). The aim of this work was to evaluate the effectiveness and safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Yera-Alos, Isis B, Alonso-Carbonell, Liuba, Valenzuela-Silva, Carmen M, Tuero-Iglesias, Angela D, Moreira-Martínez, Martha, Marrero-Rodríguez, Ivonne, López-Mola, Ernesto, López-Saura, Pedro A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3844572/
https://www.ncbi.nlm.nih.gov/pubmed/24004460
http://dx.doi.org/10.1186/2050-6511-14-44

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3844572/
https://www.ncbi.nlm.nih.gov/pubmed/24004460
http://dx.doi.org/10.1186/2050-6511-14-44

Ejemplares similares